Riskpilot← Back to searchSign inGet full accessLINDESNES APOTEK AS
ASActiveOrg 998692342Rådhusveien 14, 4520 LindesnesRetail sale of pharmaceutical products · NACE 4773Est. 20125 employees
Revenue 2025
NOK 28,7M
+2% vs 2024
EBITDA margin
8.4%
-13% vs 2024
Equity ratio
13.4%
Financial strength
Net profit 2025
NOK 2M
-10% vs 2024
| Revenue | NOK 28,7M | +2% |
| EBITDA | NOK 2,4M | -13% |
| Net profit | NOK 2M | -10% |
| Total assets | NOK 9,1M | +28% |
| Equity | NOK 1,2M | +2% |
| Employees | 5 | — |
Legal name
LINDESNES APOTEK AS
Org number
998692342
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
9. august 2012
Share capital
NOK 30 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Eie og drive apotek, herunder konsulenttjenester innenfor apotekerbransjen og lege- og helserelaterte produkter, samt øvrig virksomhet i tilknytning til dette.
Address
Rådhusveien 14, 4520 Lindesnes
Phone
+4738255530
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 22 882 | 23 797 | 24 166 | 28 224 | 28 679 |
| Staff expenses | −2 868 | −2 589 | −3 039 | −3 216 | −3 197 |
| EBITDA | 2 230 | 2 554 | 2 233 | 2 777 | 2 408 |
| Depreciation & amort. | −7 | −4 | −5 | −25 | −25 |
| EBIT | 2 223 | 2 551 | 2 228 | 2 752 | 2 383 |
| Net financials | 32 | 11 | 52 | 145 | 226 |
| Profit before tax | 2 255 | 2 562 | 2 280 | 2 897 | 2 609 |
| Tax | 496 | 564 | 506 | 643 | 581 |
| Net profit | 1 759 | 1 998 | 1 774 | 2 254 | 2 028 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 5 871 | 6 233 | 5 955 | 7 098 | 9 074 |
| Equity | 1 160 | 1 159 | 933 | 1 187 | 1 215 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 711 | 5 075 | 5 023 | 5 911 | 7 860 |
| Total debt | 4 711 | 5 075 | 5 023 | 5 911 | 7 860 |
EBITDA margin
8.4%
This company
15.8%
Market median
-47% vs market
20212025
Equity ratio
13.4%
This company
38.2%
Market median
-65% vs market
20212025
Return on equity
166.9%
This company
18.4%
Market median
+807% vs market
20212025
Net profit margin
7.1%
This company
8.1%
Market median
-12% vs market
20212025
Asset turnover
3.16×
This company
1.12×
Market median
+182% vs market
20212025
Debt / equity
6.47×
This company
0.62×
Market median
-944% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HD Chief Executive Officer | Chief Executive Officer | 2012 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 15% | 15% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of LINDESNES APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrich Devinsky | Chief Executive Officer | 0 companies |